Alzheimer's Disease News and Research

RSS
Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.
FDA accepts to review Aricept NDA for Alzheimer's disease

FDA accepts to review Aricept NDA for Alzheimer's disease

Transition stops TT-223 gastrin analogue combination clinical study in type 2 diabetes

Transition stops TT-223 gastrin analogue combination clinical study in type 2 diabetes

Common Alzheimer's disease drug enhances learning of new skills

Common Alzheimer's disease drug enhances learning of new skills

Research on BMP6 protein suggests potential therapeutic target for Alzheimer's disease

Research on BMP6 protein suggests potential therapeutic target for Alzheimer's disease

Alzheimer Society, Coffee Break commits to support Canadians living with Alzheimer's disease

Alzheimer Society, Coffee Break commits to support Canadians living with Alzheimer's disease

Same brain lesions associated with dementia responsible for mild memory loss in old age

Same brain lesions associated with dementia responsible for mild memory loss in old age

New clinical trial supports benefits of turmeric extract to people with osteoarthritis

New clinical trial supports benefits of turmeric extract to people with osteoarthritis

Mild memory loss can indicate progressive dementia: Research

Mild memory loss can indicate progressive dementia: Research

COTI selected for Canadian life sciences partnering mission

COTI selected for Canadian life sciences partnering mission

Study on spinal cord stem cells paves way for post stroke symptom treatment

Study on spinal cord stem cells paves way for post stroke symptom treatment

Stemedica Cell Technologies completes master bank of mesenchymal bone marrow-derived stem cells

Stemedica Cell Technologies completes master bank of mesenchymal bone marrow-derived stem cells

AstraZeneca Chief Scientist shares enthusiasm for collaborative clinical research

AstraZeneca Chief Scientist shares enthusiasm for collaborative clinical research

Metabolon receives patent for metabolic age analysis

Metabolon receives patent for metabolic age analysis

Structural component inside neurons dances when connections are strengthened

Structural component inside neurons dances when connections are strengthened

Researchers to discuss brain's secrets at neuroscience conference

Researchers to discuss brain's secrets at neuroscience conference

Researchers identify novel molecular pathway of Parkinson’s disease

Researchers identify novel molecular pathway of Parkinson’s disease

New book relates mercury in vaccines to autism

New book relates mercury in vaccines to autism

Cell quality control mechanism research paves way for new understanding of neurodegenerative diseases

Cell quality control mechanism research paves way for new understanding of neurodegenerative diseases

Researchers find amyloid precursor protein function in Alzheimer's disease

Researchers find amyloid precursor protein function in Alzheimer's disease

Researchers develop GAL4/UAS system to study human neurological diseases

Researchers develop GAL4/UAS system to study human neurological diseases

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.